(19)
(11) EP 2 905 338 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.01.2018 Bulletin 2018/04

(45) Mention of the grant of the patent:
02.08.2017 Bulletin 2017/31

(21) Application number: 14198318.9

(22) Date of filing: 22.06.2011
(51) International Patent Classification (IPC): 
C12N 15/85(2006.01)
C07K 16/00(2006.01)
C07K 16/18(2006.01)
 A01K 67/027(2006.01)
C07K 16/46(2006.01)

(54)

Transgenic mice with a modified endogenous lambda immunoglobulin locus

Transgene Mäuse mit einer modifizierten endogenen lambda Immunglobulin-Locus

Souris transgéniques avec un locus endogène d'immunoglobulin lambda modifié

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 22.06.2010 US 357314 P
22.06.2010 US 357317 P

(43) Date of publication of application:
12.08.2015 Bulletin 2015/33

(60) Divisional application:
17162880.3 / 3205726

(62) Application number of the earlier application in accordance with Art. 76 EPC:
11728508.0 / 2480675

(73) Proprietor: Regeneron Pharmaceuticals, Inc.
Tarrytown, NY 10591 (US)

(72) Inventors:
  • Murphy, Andrew J.
    Croton-on-Hudson, NY 10520 (US)
  • Stevens, Sean
    San Diego, CA 92122 (US)
  • Gurer, Cagan
    Valhalla, NY 10595 (US)
  • Macdonald, Lynn
    White Plains, NY 10605 (US)
  • Hosiawa, Karolina A.
    Tarrytown, NY 10591 (US)

(74) Representative: J A Kemp 
14 South Square Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB)


(56) References cited: : 
WO-A1-00/26373
WO-A2-2008/054606
WO-A2-2010/039900
US-A1- 2003 217 373
 WO-A1-2011/004192
WO-A2-2009/143472
US-A1- 2002 026 036
US-A1- 2006 015 957
   
  • POPOV A V ET AL: "A HUMAN IMMUNOGLOBULIN L LOCUS IS SIMILARLY WELL EXPRESSED IN MICE AND HUMANS", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 189, no. 10, 17 May 1999 (1999-05-17) , pages 1611-1619, XP000891331, ISSN: 0022-1007, DOI: 10.1084/JEM.189.10.1611
  • GORMAN J R ET AL: "THE LGK 3' ENHANCER INFLUENCES THE RATIO OF LGK VERSUS LGL B LYMPHOCYTES", IMMUNITY, CELL PRESS, US, vol. 5, no. 3, September 1996 (1996-09), pages 241-252, XP000891305, ISSN: 1074-7613, DOI: 10.1016/S1074-7613(00)80319-2
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).